LFLY vs. BCEL, HCTI, TCON, VERO, XCUR, TMDIF, STSS, EVOK, PEAR, and BACK
Should you be buying Leafly stock or one of its competitors? The main competitors of Leafly include Atreca (BCEL), Healthcare Triangle (HCTI), TRACON Pharmaceuticals (TCON), Venus Concept (VERO), Exicure (XCUR), Titan Medical (TMDIF), Sharps Technology (STSS), Evoke Pharma (EVOK), Pear Therapeutics (PEAR), and IMAC (BACK). These companies are all part of the "medical" sector.
Leafly (NASDAQ:LFLY) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Leafly has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Atreca has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.
In the previous week, Leafly and Leafly both had 1 articles in the media. Leafly's average media sentiment score of 1.43 beat Atreca's score of 0.00 indicating that Leafly is being referred to more favorably in the media.
Leafly has higher revenue and earnings than Atreca. Leafly is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
Leafly presently has a consensus price target of $6.00, indicating a potential upside of 240.91%. Given Leafly's stronger consensus rating and higher probable upside, research analysts clearly believe Leafly is more favorable than Atreca.
Atreca has a net margin of 0.00% compared to Leafly's net margin of -16.20%. Leafly's return on equity of 0.00% beat Atreca's return on equity.
Atreca received 92 more outperform votes than Leafly when rated by MarketBeat users. Likewise, 67.86% of users gave Atreca an outperform vote while only 37.50% of users gave Leafly an outperform vote.
15.6% of Leafly shares are owned by institutional investors. Comparatively, 37.5% of Atreca shares are owned by institutional investors. 11.3% of Leafly shares are owned by insiders. Comparatively, 11.3% of Atreca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Leafly beats Atreca on 8 of the 15 factors compared between the two stocks.
Get Leafly News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
